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Omar Faiz, Julian Teare, Richard J Lilford, Dion Morton, Jane Wardle, Steve Halligan, for the SIGGAR investigators*
Summary
Background Colonoscopy is the gold-standard test for investigation of symptoms suggestive of colorectal cancer; 
computed tomographic colonography (CTC) is an alternative, less invasive test. However, additional investigation 
after CTC is needed to conﬁ rm suspected colonic lesions, and this is an important factor in establishing the 
feasibility of CTC as an alternative to colonoscopy. We aimed to compare rates of additional colonic investigation 
after CTC or colonoscopy for detection of colorectal cancer or large (≥10 mm) polyps in symptomatic patients in 
clinical practice.
Methods This pragmatic multicentre randomised trial recruited patients with symptoms suggestive of colorectal 
cancer from 21 UK hospitals. Eligible patients were aged 55 years or older and regarded by their referring clinician as 
suitable for colonoscopy. Patients were randomly assigned (2:1) to colonoscopy or CTC by computer-generated 
random numbers, in blocks of six, stratiﬁ ed by trial centre and sex. We analysed the primary outcome—the rate of 
additional colonic investigation—by intention to treat. The trial is an International Standard Randomised Controlled 
Trial, number 95152621.
Findings 1610 patients were randomly assigned to receive either colonoscopy (n=1072) or CTC (n=538). 30 patients 
withdrew consent, leaving for analysis 1047 assigned to colonoscopy and 533 assigned to CTC. 160 (30·0%) patients 
in the CTC group had additional colonic investigation compared with 86 (8·2%) in the colonoscopy group (relative 
risk 3·65, 95% CI 2·87–4·65; p<0·0001). Almost half the referrals after CTC were for small (<10 mm) polyps or 
clinical uncertainty, with low predictive value for large polyps or cancer. Detection rates of colorectal cancer or large 
polyps in the trial cohort were 11% for both procedures. CTC missed 1 of 29 colorectal cancers and colonoscopy 
missed none (of 55). Serious adverse events were rare.
Interpretation Guidelines are needed to reduce the referral rate after CTC. For most patients, however, CTC provides 
a similarly sensitive, less invasive alternative to colonoscopy.
Funding NIHR Health Technology Assessment Programme, NIHR Biomedical Research Centres funding scheme, 
Cancer Research UK, EPSRC Multidisciplinary Assessment of Technology Centre for Healthcare, and NIHR 
Collaborations for Leadership in Applied Health Research and Care.
Introduction 
Colonoscopy is the gold-standard investigation of the 
colon, oﬀ ering a sensitive luminal examination that 
allows biopsy samples to be taken for deﬁ nitive diagnosis. 
However, older patients and those with comorbidities are 
more likely to have an incomplete or diﬃ  cult colon-
oscopy1,2 and are at greater risk of adverse events than 
younger patients with no comorbidities.3,4 Therefore, in 
some circumstances, it might be preferable to use an 
alternative ﬁ rst-line investi gation for patients with 
symptoms suggestive of colo rectal cancer.
One possibility is computed tomographic colon-
ography (CTC), or virtual colonoscopy—a relatively new 
radio logical technique for imaging the large bowel. 
CTC is less invasive than colonoscopy, and might be 
safer5 and more acceptable6–8 to patients. Most patients 
having colonoscopy need to be sedated, which is not 
necessary for CTC. However, if lesions needing biopsy 
or removal are detected at CTC, colon oscopy is usually 
needed. CTC also detects extracolonic lesions, which 
might explain symptoms but might also lead to 
additional investi gations that ultimately bring no 
clinical beneﬁ t. So far, CTC and colonoscopy in 
symptomatic patients have never been compared in a 
randomised trial.
Systematic reviews suggest that CTC and colonoscopy 
have similar sensitivity for detection of colorectal can-
cer9,10 and large polyps10,11 if undertaken in accordance 
with best practice12,13 by experienced practitioners. As a 
result, the sample size needed for a non-inferiority trial 
powered on detection rates would be unfeasibly large. 
Comparison of the beneﬁ ts and costs of the two 
procedures will therefore depend on other factors. One 
of the most important is the need for additional 
investigation after CTC, which is likely to determine 
the practicality of more widespread use of CTC as a 
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diagnostic test. However, colonoscopy can also gener ate 
further tests because of incomplete examin ations— 
a survey undertaken before our study reported a non-
completion rate that exceeded 20% in routine UK 
practice.14
We have undertaken two pragmatic multicentre 
randomised trials in patients with symptoms suggestive 
of colorectal cancer. In a parallel trial,15 we compared the 
relative sensitivity of CTC with that of barium enema in 
patients referred for radiological investigation of the 
colon. In this trial, we compared the need for additional 
diagnostic tests after CTC versus colonoscopy in patients 
regarded as suitable for colonoscopy by their referring 
clinician. Our studies of patient acceptability16,17 and cost-
eﬀ ectiveness are reported elsewhere.18
Methods
Study design and participants
The design and rationale of this multicentre randomised 
trial have been published previously.19 The trial protocol 
can be found online. Research nurses at 21 UK National 
Health Service (NHS) teaching and general hospitals 
recruited patients referred by their family doctor for 
investigation of symptoms sugges tive of colorectal 
cancer. Patients were eligible if they were aged 55 years 
or older, were ﬁ t to undergo full bowel preparation, had 
no known genetic pre disposition to cancer, had no 
history of inﬂ am matory bowel disease, had not had a 
whole-colon examination in the past 6 months, and 
were not in active follow-up for previous colorectal 
cancer. We obtained demographic and baseline clinical 
data such as age, sex, and symptoms for all potentially 
eligible patients. The consulting clinician then decided 
in line with usual practice whether to investigate the 
patient using colon oscopy or barium enema (the default 
examinations). We created two parallel trials and, 
within each, patients were randomly assigned to the 
default examination or CTC.19 No patients were enrolled 
in both trials.
We obtained ethical approval from the Northern and 
Yorkshire Multicentre Research Ethics Committee and 
from all participating hospitals. The trials were super-
vised by independent data moni toring and trial steering 
committees. All patients gave informed written consent.
Randomisation
We randomly allocated patients (2:1) to receive either 
colonoscopy or CTC. A statistician (RE) generated the 
randomisation codes at a remote site, and codes were 
kept concealed until interventions were assigned. RE was 
involved in the design of both the trial and its database, 
but had no involvement in data collection or inter-
pretation. Randomisation was done centrally by com-
puter random number generation, in blocks of six, 
stratiﬁ ed by centre and patient sex. Participants and 
those administering the procedures were not masked to 
the assigned study intervention.
Procedures
CTC and colonoscopy were undertaken after full bowel 
preparation, and in accordance with contemporary 
guidelines on best practice.20,21 For CTC, multidetector-
row scanners (minimum four rows) were used with a 
maximum detector collimation of 2·5 mm and a pitch 
that allowed abdominal coverage (40 cm) within one 
breath-hold (20 s). Prone and supine scans were recom-
mended. Readers used two-dimensional (2D) and three-
dimensional (3D) visualisation as needed, but a minimum 
requirement was a primary 2D analysis with volume or 
surface rendering for problem solving. The reading 
platform was decided according to local preference, as 
was use of intravenous contrast and faecal tagging. 
Computer-assisted detection was available.
217 gastroenterologists or colorectal surgeons under-
took the colonoscopies. 41 radiologists sub specialising in 
gastro intestinal radiology interpreted the CTC studies. 
All radiologists were familiar with interpreting the pro-
cedure, and those who had read fewer than 100 cases, or 
who desired additional training, attended a supple-
mentary 2 day course.
For each procedure, the radiologist or endoscopist 
issued a report as usual and completed a case report 
form. Flexible sigmoidoscopy (FS) was undertaken 
before CTC in some hospitals. Details of these FS 
examinations were recorded, including any lesions seen.
Adverse events within 24 h of the randomised 
procedure were recorded on the case report form, or on a 
question naire completed by patients the following 
morning. Details of unplanned hospital admissions 
within 30 days were collected by manually searching 
hospitals’ patient administration systems.
Referrals for additional investigation were made at the 
discretion of local clinicians, and research nurses collected 
the reports from these procedures. 
Outcomes
The primary outcome was the proportion of patients who 
had additional colonic investigation. Secondary outcomes 
were detection rates of colorectal cancer or large polyps, 
other colorectal diagnoses, miss rates for colorectal 
cancer, extracolonic cancer diagnoses, all-cause mortality, 
and serious adverse events. We also analysed extracolonic 
ﬁ ndings at CTC.
We deﬁ ned additional colonic investigation as any 
subsequent examination of the colon until diagnosis 
(usually histological conﬁ rmation of a cancer or polyp), or 
until a patient was referred back to their family doctor.
Our deﬁ nition of colorectal cancer included all cancers 
with International Statistical Classiﬁ cation of Diseases and 
Related Health Problems, revision 10 (ICD-10) site codes 
C18–C20. Polyp size was deﬁ ned as the largest measure-
ment at endoscopy, histology, or surgery. Details of cancer 
diagnoses (colonic and extracolonic) and deaths in the 
trial cohort were obtained from the NHS Information 
Centre (NHSIC). A colorectal cancer was deﬁ ned as 
For the trial protocol see http://
www.hta.ac.uk/project/1366.asp
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missed if it was identiﬁ ed through NHSIC as occurring 
within 36 months of randomisation, but was not detected 
by the randomised procedure or mentioned in the 
patient’s discharge letter.
Extracolonic cancers included all reported primary 
malignant neoplasms, excluding colorectal cancers 
(C18–C20) and non-melanoma malignant neoplasms of 
the skin (C44).
A serious adverse event was deﬁ ned as any incident 
causing hospital admission, death, threat to life, or 
permanent impairment.22 An expert panel consisting of a 
radiologist, a gastroenterologist, and a colorectal surgeon 
reviewed reasons for unplanned hospital admissions and 
deaths within 30 days to decide whether any were 
attributable to a randomly assigned procedure (reviewers 
were masked to the assigned procedure). Panel members 
assessed cases independently and a consensus was 
reached when any disagreement arose.
Patients with extracolonic ﬁ ndings at CTC were followed 
up until either a diagnosis was given, the patient was put 
into regular surveillance, or a decision was made not to 
investigate further. The expert panel reviewed diagnoses 
resulting from extracolonic ﬁ ndings at CTC to establish 
whether these diagnoses could have explained patients’ 
presenting symptoms.
Statistical analysis
We estimated that a sample size of 1430 would give 
80% power to detect a signiﬁ cant diﬀ erence in rates of 
additional colonic investigation at α=0·05 (two-tailed), 
assuming that 14% of patients after colonoscopy and 20% 
after CTC would need additional colonic investigation, 
and with 2:1 randomisation in favour of colonoscopy. The 
primary and secondary outcomes were analysed by 
intention to treat, except for colorectal cancer miss rates 
and adverse events, which were analysed only in patients 
who had their randomised procedure. The analysis of 
detection rates was per patient, using the most advanced 
colonic lesion diagnosed.
We analysed all extracolonic cancers diagnosed within 
36 months of randomisation, and calculated expected 
numbers by applying age-sex-speciﬁ c cancer incidence for 
the general population to our cohort, having adjusted for 
reported mortality.23 We compared incidence assuming a 
Poisson distribution.
Categorical outcomes were compared using Pearson’s χ² 
test or Fisher’s exact test, as appropriate. We calculated 
relative risks (RRs) with 95% CIs. We showed RRs for the 
primary outcome by age group (<65 years or ≥65 years) 
and sex using forest plots, and used tests of interaction 
(Mantel-Haenszel) to identify signiﬁ cant diﬀ erences. To 
check whether clustering by trial centre aﬀ ected results, 
we also analysed the primary outcome using random 
eﬀ ects logistic models allowing for heterogeneity in the 
outcome and intervention eﬀ ects by centre (odds ratios 
were compared).24 All tests were two-tailed with signiﬁ cance 
assigned at 5%. We analysed the data using Stata 10.1.
Figure 1: Trial proﬁ le
*Reasons why patients were not randomised can be found in the appendix. †11 had an alternative whole-colon 
examination; 19 did not have a whole-colon examination. ‡16 had an alternative whole-colon examination; 64 did 
not have a whole-colon examination. 
8484 symptomatic patients assessed for eligibility
3036 excluded*
 2176 clinician decision
 834 patient decision
 26 unknown
1047 analysed
 967 had colonoscopy
 80 did not have colonoscopy‡
533 analysed
 503 had CT colonography
 30 did not have CT colonography†
3838 entered CT colonography 
 vs barium enema trial15
1610 entered CT colonography vs colonoscopy trial
1072 randomly assigned to colonoscopy
25 withdrew consent5 withdrew consent
538 randomly assigned to CT colonography
Patients included in CT 
colonography vs 
colonoscopy trial
Comparison of included and excluded 
patients
CT 
colonography 
(n=533)
Colonoscopy 
(n=1047)
Patients 
included in CT 
colonography 
vs colonoscopy 
trial (n=1580)
Excluded 
patients* 
(n=3036)
p value
Sex 0·0074
Male 240 (45%) 476 (45%) 716 (45%) 1251 (41%)
Female 293 (55%) 571 (55%) 864 (55%) 1785 (59%)
Age (years) <0·0001
55–64 217 (41%) 384 (37%) 601 (38%) 802 (26%)
65–74 186 (35%) 377 (36%) 563 (36%) 1045 (34%)
75–84 113 (21%) 253 (24%) 366 (23%) 930 (31%)
≥85 17 (3%) 33 (3%) 50 (3%) 259 (9%)
Symptoms†
Change in bowel habit 383 (72%) 772 (74%) 1155 (73%) 1926 (63%) <0·0001
Harder, less frequent 66 (12%) 126 (12%) 192 (12%) 297 (10%) ··
Looser, more frequent 214 (40%) 410 (39%) 624 (39%) 1049 (35%) ··
Variable 54 (10%) 124 (12%) 178 (11%) 180 (6%) ··
Unspeciﬁ ed 49 (9%) 112 (11%) 161 (10%) 400 (13%) ··
Rectal bleeding 240 (45%) 432 (41%) 672 (43%) 1169 (39%) 0·0080
Abdominal pain 124 (23%) 227 (22%) 351 (22%) 574 (19%) 0·0077
Anaemia 60 (11%) 140 (13%) 200 (13%) 620 (20%) <0·0001
Weight loss 82 (15%) 155 (15%) 237 (15%) 500 (16%) 0·19
Other symptoms 102 (19%) 172 (16%) 274 (17%) 585 (19%) 0·11
Data are number (%) unless otherwise speciﬁ ed. *Patients excluded from both this trial and the parallel CT 
colonography versus barium enema trial. †Some patients reported more than one symptom.
Table 1: Characteristics of patients included in this trial versus excluded patients
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The trial is an International Standard Randomised 
Controlled Trial, number 95152621.
Role of the funding source
The primary funder (the National Institute for Health 
Research) stipulated a randomised controlled design, but 
no funders or providers of equipment were involved in the 
collection, analysis, or interpretation of data, nor in the 
writing or submitting of the report. WA, ED, KW, IK-H, 
and SH had full access to study data, whereas CvW, GY, 
RJL, and JW had access to subsets of the data. All authors 
take responsibility for the decision to submit for publication.
Results
Recruitment for both trials began in March, 2004, and 
was completed in December, 2007. Of 8484 potentially 
eligible patients, 3036 were not included because either 
they or their clinician declined consent (for speciﬁ c 
reasons, see appendix) and 3838 entered the accom-
panying CTC versus barium enema trial.15 Of the 
remaining 1610 patients who entered the CTC versus 
colonoscopy trial, 30 subsequently withdrew consent 
(25 [2·3%] in the colonoscopy group and ﬁ ve [0·9%] in 
the CTC group), leaving 1580 for analysis (1047 assigned 
to colonoscopy and 533 to CTC; ﬁ gure 1).
CT 
colonography 
(n=533)
Colonoscopy 
(n=1047)
Relative risk 
(95% CI)
p value CT colonography 
(n=533)
Colonoscopy 
(n=1047)
Men 
(n=240)
Women 
(n=293)
Men 
(n=476)
Women 
(n=571)
All referrals for additional colonic 
investigation
160* (30·0%) 86† (8·2%) 3·65 (2·87–4·65) <0·0001 87 (36·2%) 73 (24·9%) 27 (5·7%) 59 (10·3%)
Colorectal cancer or polyp ≥10 mm 
suspected
83 (15·6%) 12‡ (1·1%) 13·59 (7·48–24·66) <0·0001 45 (18·7%) 38 (13·0%) 4 (0·8%) 8 (1·4%)
Colorectal cancer 47 10 ·· ·· 25 22 4 6
Polyp ≥10 mm 36 2 ·· ·· 20 16 0 2
Smaller polyp suspected 49 (9·2%) 1§ (0·1%) ·· <0·0001 27 (11·2%) 22 (7·5%) 1 (0·2%) 0
8–9 mm 14 1 ·· ·· 8 6 1 0
6–7 mm 22 0 ·· ·· 14 8 0 0
≤5 mm 13 0 ·· ·· 5 8 0 0
Clinical uncertainty (no lesions seen) 28 (5·3%) 73 (7·0%) 0·75 (0·49–1·15) 0·19 15 (6·3%) 13 (4·4%) 22 (4·6%) 51 (8·9%)
Inadequate examination 18 72 ·· ·· 10 8 21 51
Adequate examination 10 1 ·· ·· 5 5 1 0
Data are number, or number (%), unless otherwise speciﬁ ed. *150 patients were referred to endoscopy and ten directly to surgery. †16 patients were referred to endoscopy, 
63 to radiology, and seven directly to surgery. ‡Comprises ten patients in whom biopsy samples were not taken at colonoscopy or were inconclusive, and two patients 
referred after an alternative procedure. §Patient referred after an alternative procedure.
Table 2: Additional colonic investigation by reason for investigation, overall and by sex
CT colonography Colonoscopy
Additional 
colonic 
procedure 
undertaken
Colorectal 
cancer 
detected
Polyp 
≥10 mm 
detected
Colorectal 
cancer or polyp 
≥10 mm 
detected
Additional 
colonic 
procedure 
undertaken
Colorectal 
cancer 
detected
Polyp 
≥10 mm 
detected
Colorectal 
cancer or 
polyp ≥10 mm 
detected
All referrals for additional colonic investigation 160 29 26 55 (34%) 86 12 3 15 (17%)
Colorectal cancer or polyp ≥10 mm suspected 83 29 22 51 (61%) 12 9 2 11 (92%)
Colorectal cancer 47 27 3 30 10 9 1 10
Polyp ≥10 mm 36 2 19 21 2 0 1 1
Smaller polyp suspected 49 0 3 3 (6%) 1 0 0 0
8–9 mm 14 0 2 2 1 0 0 0
6–7 mm 22 0 0 0 0 0 0 0
≤5 mm 13 0 1* 1 0 0 0 0
Clinical uncertainty (no lesions seen) 28 0 1 1 (4%) 73 3 1 4 (5%)
Inadequate examination 18 0 1 1 72 3 1 4
Adequate examination 10 0 0 0 1 0 0 0
Data are number, or number (%). Only the most advanced lesion per patient is presented. *5 mm transverse colon polyp at CT colonography, and a 10 mm pedunculated 
sigmoid colon polyp at subsequent colonoscopy.
Table 3: Results of additional colonic investigation, by reason for investigation
See Online for appendix
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The median age of participants in this trial was 68 years 
(IQR 61–75) and 864 (55%) were women. The most 
frequent presenting symptoms were change in bowel 
habit, rectal bleeding, and abdominal pain (table 1). 
Participants included in this trial were more likely to be 
male, younger, and to present with a change in bowel 
habit, rectal bleeding, or abdominal pain than were 
excluded patients. They were less likely to present with 
anaemia (table 1).
The proportion of patients who had their assigned 
procedure did not diﬀ er signiﬁ cantly between study 
groups (967 [92·4%] of 1047 in the colonoscopy group vs 
503 [94·4%] of 533 in the CTC group; p=0·14). Reasons 
why patients did not have the procedure are outlined in 
the appendix. Of those patients who did not have the 
assigned pro cedure, 16 (20%) of 80 in the colonoscopy 
group and 11 (37%) of 30 in the CTC group had an 
alternative whole-colon examination (ﬁ gure 1). FS was 
undertaken before the scheduled random ised pro-
cedure in eight patients assigned to CTC but none 
assigned to colonoscopy. 
Additional diagnostic investigation of the colon was 
undertaken more than three times as often in patients 
assigned to CTC than assigned to colonoscopy (160 [30·0%] 
of 533 vs 86 [8·2%] of 1047; p<0·0001; table 2). We obtained 
similar results when we analysed rates only in patients 
who had their randomised procedure (data not shown). 
Models controlling for clustering by trial centre showed no 
attenuation of eﬀ ect (data not shown).
In the colonoscopy group, 118 (11·3%) patients had 
a colonoscopy that was incomplete (did not reach the 
caecum), and 72 (6·9%) had an additional procedure for 
this reason. A further 13 (1·2%) patients were referred to 
conﬁ rm a suspected cancer or polyp (because biopsy 
samples were not taken or were inadequate for histo-
logical con ﬁ rmation), and one patient was referred for an 
additional procedure because of persistent symptoms 
(table 2). By comparison, 83 patients (15·6%) in the CTC 
group were referred to investigate a suspected cancer or 
polyp of 10 mm or larger, 49 (9·2%) for smaller polyps, 
and 28 (5·3%) because of an inadequate examination or 
clinical uncertainty (table 2). All 29 cancers and 22 of the 
26 large polyps identiﬁ ed at subsequent colonic investi-
gations in the CTC group were in patients in whom a 
large lesion had been seen at the ﬁ rst examination; the 
yield in patients referred for small polyps or clinical 
uncertainty was low (table 3).
Relative referral rates diﬀ ered signiﬁ cantly between 
men and women (p=0·0002). Men were more than six 
times as likely to have an additional colonic examination 
after CTC than after colonoscopy, whereas women were 
just over twice as likely to do so (ﬁ gure 2). Results did not 
diﬀ er sig niﬁ cantly by age group (p=0·32; ﬁ gure 2).
Of 1047 patients assigned to colonoscopy, 119 (11·4%) 
were diagnosed with colorectal cancer or a large polyp: 
116 (11·1%) at colonoscopy and three (0·3%) after an 
alternative procedure. By comparison, 57 (10·7%) of 
533 patients assigned to CTC were diagnosed with 
colorectal cancer or a large polyp: 54 (10·1%) at CTC, 
two (0·4%) at previous FS, and one (0·2%) after an 
alternative procedure (see footnote to table 4 for 
histological diagnoses of cancers and large polyps). The 
overall detection rate of colorectal cancer or large polyps 
did not diﬀ er between groups (RR 0·94, 95% CI 
0·70–1·27; p=0·69). Analysis of detection rates only in 
patients who had their randomised procedure (and 
excluding lesions detected at previous FS) gave similar 
results (table 4).18
We also analysed other colorectal ﬁ ndings. A 
signiﬁ cantly greater proportion of patients in the CTC 
group were diagnosed with diverticulosis than were 
those in the colonoscopy group (287 [54%] of 533 assigned 
to CTC vs 366 [35%] of 1047 assigned to colonoscopy; 
p<0·0001), whereas colitis (4 [1%] vs 34 [3%]; p=0·0022) 
and anal pathology (13 [2%] vs 73 [7%]; p=0·0002) were 
diagnosed more frequently in the colonoscopy group 
than in the CTC group. Other ﬁ ndings occurred in 
numbers too low to be analysed.
Figure 2: Additional colonic investigation by sex and age group
*Relative to the mean eﬀ ect.
Colonoscopy Relative risk (95% CI)CT colonography
Sex
Men
Women
χ21=14·169; p=0·0002
87/240 (36·2%)
73/293 (24·9%)
27/476 (5·7%)
59/571 (10·3%)
6·39 (4·27–9·56)
2·41 (1·76–3·30)
Age (years)
<65
≥65
χ21=0·984; p=0·32
68/217 (31·3%)
92/316 (29·1%)
28/384 (7·3%)
58/663 (8·7%)
4·30 (2·86–6·46)
3·33 (2·47–4·49)
All patients
p<0·0001
160/533 (30·0%) 86/1047 (8·2%) 3·65 (2·87–4·65)
Favours CT colonography* Favours colonoscopy
3·65321 5 7 10
CT 
colonography
Colonoscopy Relative risk (95% CI) p value
All patients, n 533 1047
Colorectal cancer or polyp ≥10 mm 57 (10·7%) 119 (11·4%) 0·94 (0·70–1·27) 0·69
Colorectal cancer 30* (5·6%) 58† (5·5%) 1·02 (0·66–1·56) 0·94
Polyp ≥10 mm 27‡ (5·1%) 61§ (5·8%) 0·87 (0·56–1·35) 0·53
Patients who had their randomised 
procedure, n¶
503 967
Colorectal cancer or polyp ≥10 mm 54 (10·7%) 116 (12·0%) 0·89 (0·66–1·21) 0·47
Colorectal cancer 28 (5·6%) 55 (5·7%) 0·98 (0·63–1·52) 0·92
Polyp ≥10 mm 26 (5·2%) 61 (6·3%) 0·82 (0·52–1·28) 0·38
Data are number, or number (%), unless otherwise speciﬁ ed. Only the most advanced lesion per patient is presented. 
*29 adenocarcinomas and one non-Hodgkin lymphoma. †55 adenocarcinomas, one carcinoid tumour, and two cancers 
that were not histologically conﬁ rmed. ‡24 adenomas and three hyperplastic polyps. §52 adenomas, four hyperplastic 
polyps, three serrated adenomas, one juvenile polyp, and one polyp excised but not retrieved. ¶Excludes lesions 
detected previously by ﬂ exible sigmoidoscopy. 
Table 4: Detection rates of colorectal cancer and large polyps
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At least one previously unknown extracolonic ﬁ nding 
was reported in 287 (60·4%) of the 475 patients who had 
CTC and did not have colorectal cancer diagnosed before 
discharge. A referral for additional investigation was 
made in 48 (10·1%) patients, leading to diagnosis of 
extracolonic malignancy in nine (see appendix). No 
patients had aortic aneurysms of 5·5 cm diameter or 
larger (the recom mended threshold for surgical referral) 
but nine had aneurysms of 3·0–5·4 cm (recommended 
for surveillance).25 Of 48 patients who had additional pro-
cedures to investigate an extracolonic ﬁ nding, 17 (35%) 
were given a diagnosis that explained at least one of their 
presenting symptoms. A more detailed analysis will be 
published elsewhere.18 
We analysed the data in June, 2012, when registration 
was reported to be 97% complete for cancers diagnosed 
until December, 201026 (at which point all patients had 
been followed up for at least 36 months), and all deaths 
until December, 2011, had been registered.27 At the time 
of analysis (median follow-up for deaths 5·2 years, IQR 
4·6–5·9), 154 (14·7%) patients assigned to colonoscopy 
and 63 (11·8%) assigned to CTC had died (p=0·11).
Of the 503 patients who had CTC, 28 (5·6%) received a 
colorectal cancer diagnosis as a result of the procedure 
(table 4), and one had an additional cancer that was 
diagnosed during the 3 year follow-up, giving a miss rate 
of one in 29 (3·4%). Of the 967 patients who had 
colonoscopy, 55 (5·7%) were diagnosed with colorectal 
cancer (table 4) and no cancers were missed.
During the 3 year follow-up, 27 primary extracolonic 
cancers were diagnosed in the CTC group and 56 in the 
colonoscopy group (see appendix); incidence did not 
diﬀ er between groups (17·6 per 1000 person-years in the 
CTC group vs 18·7 per 1000 person-years in the 
colonoscopy group; incidence rate ratio [IRR] 0·94, 
95% CI 0·59–1·49; p=0·79; appendix). In the ﬁ rst year, 
rates were more than twice as high as expected (IRR 
2·33, 1·40–3·89; p=0·0007), but again rates did not diﬀ er 
signiﬁ cantly between the CTC and colonoscopy groups 
(IRR 0·95, 0·53–1·73; p=0·88). CTC detected nine (56%) 
of 16 extra colonic cancers diagnosed during the ﬁ rst year. 
Colonoscopy detected one extracolonic cancer: a lung 
primary diagnosed via a colonic metastasis.
Minor adverse eﬀ ects are reported elsewhere;17 we 
report more serious adverse events here. An unplanned 
hospital admission within 30 days occurred in 
12 patients after colonoscopy and six after CTC. The 
expert panel judged four admissions as possibly 
attributable to a randomised procedure. Three occurred 
after colonoscopy (one abdominal pain, one rectal 
bleeding, one diarrhoea and vomiting); polypectomy 
was not undertaken at any of these examinations. 
Another patient had CTC followed by colonoscopy 
22 days later for removal of two large lesions; the 
patient was then admitted immediately because of a 
suspected perforation but was discharged the following 
day. No conﬁ rmed perforations were reported. One 
patient died within 30 days, after surgery for colorectal 
cancer detected at CTC.
Discussion
This is the ﬁ rst randomised trial comparing CTC and 
colonoscopy for investigation of patients with symptoms 
suggestive of colorectal cancer, and the ﬁ rst trial to 
compare rates of additional colonic investigation when 
the two tests are used in normal clinical practice (see 
panel). We report that 30% of patients had additional 
colonic investigation after CTC, compared with only 8% 
after colonoscopy. Almost half the referrals after CTC 
were for polyps smaller than 10 mm or because of clinical 
uncertainty, with low predictive value for colorectal cancer 
or large polyps. We also found a signiﬁ cant diﬀ er ence in 
relative referral rates by sex. Men were more likely than 
women to have a second examination after CTC, usually 
because a cancer or polyp was detected, whereas women 
were more likely than men to have a second exam ination 
after colonoscopy, usually because their colonoscopy was 
incomplete. This conﬁ rms results from other studies 
showing that women tolerate colonoscopy less well and 
have fewer polyps than men do.1,28
Most prospective studies of CTC have been within-
patient comparisons in which all patients receive colon-
oscopy, irrespective of ﬁ ndings at CTC.11 Such studies do 
not capture the uncertainties faced by radiol ogists and 
referring clinicians when dealing with a symptomatic 
population. If CTC is to become more widely used as an 
alternative to colonoscopy, the referral rate we report for 
subsequent endoscopic investigation is unacceptably high, 
particularly when it is considered that only a third of 
referred patients were found to have colorectal cancer or a 
large polyp, and concern has been expressed by endo-
scopists that colonoscopies after false-positive CTCs take 
signiﬁ cantly longer than routine examinations.29
Many of these referrals for colonoscopy might be 
avoidable. For example, small lesions rarely cause symp-
toms and carry a low risk of cancer. If, as we suggest,15 the 
threshold for referral had been set at 8 mm, this would 
have reduced the referral rate to 23% with minimal loss of 
sensitivity. Further reductions could be made through the 
use of oral contrast to label residual ﬂ uid and stool (faecal 
tagging), which was rarely used in our study but is 
becoming widespread in clinical practice.30 Faecal tagging 
might give radiologists greater conﬁ dence in the presence 
or absence of lesions,31 poten tially reducing referrals due 
to poor bowel preparation or to lesions identiﬁ ed with low 
certainty. Evidence-based referral guidelines are also 
needed, both for radiologists and referring clinicians.
In our trial, the unadjusted non-completion rate for 
colon oscopy was 11%, with 7% of patients having an 
additional examination for this reason. Although com ple-
tion rates have increased substantially since the pub-
lication of a UK audit in 2004,14 there might be a limit to 
what is achievable in symptomatic patients: one recent 
audit showed an unadjusted non-completion rate of 8% for 
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all colonoscopies32 and another showed a rate of 12% for 
non-screening colonoscopies;33 similar to what we report.
Meta-analysis shows that CTC has a sensitivity for colo-
rectal cancer of 96% when compared with colon oscopy as 
the reference standard.9 Several audits have shown a 
cancer miss rate by colonoscopy of 5%.34–36 In our trial, 
CTC missed one cancer (of 29) whereas colonoscopy 
missed none (of 55). For large polyps, the sensitivity of 
CTC relative to colonoscopy in our trial was in broad 
agreement with average sensitivities reported in meta-
analyses: 85%11 and 93%.10 However, results of studies vary 
widely, which has been attributed mainly to diﬀ erences in 
the equipment used11 and in the skill of radiologists.37 If 
diagnostic standards are to be maintained as use of CTC 
becomes more widespread, formal training and testing 
will be needed, with retraining for those who do not 
achieve a suitable level.38 Minimum standards for reporting 
and regular audit are also needed, as exist for colonoscopy.39
Our analysis of colonic ﬁ ndings showed that colitis was 
diagnosed signiﬁ cantly more frequently in patients 
having colonoscopy than in those having CTC, making 
CTC an unsuitable test when colitis is suspected.
Extracolonic abnormalities were reported in around 
60% of patients who had CTC in both this and the parallel 
trial;15 a rate similar to that seen in screening popu-
lations.40,41 Most extracolonic ﬁ ndings were judged to be 
clinically unimportant, and rates of additional extracolonic 
investi gation after CTC (10% in this trial and 7% in the 
parallel trial) were similar to those reported in two 
retrospective UK studies of symptomatic patients, and in 
an older asymptomatic US cohort.41–43 In patients who 
were investigated, only a third received a diagnosis that 
explained at least one of their presenting symptoms.
The proportion of patients with an extracolonic cancer 
diagnosed within 3 years was similar after CTC and 
colonoscopy (around 5%), and time to diagnosis was not 
shorter in the CTC group (appendix). Around 60% of 
diagnoses were made during the ﬁ rst year, suggesting 
that they resulted from ongoing investigation of patients’ 
original symptoms. Clearly, when symptoms are vague 
but colorectal cancer is suspected, clinicians are faced 
with a choice: to undertake a speciﬁ c colonic examination 
such as colonoscopy and refer for additional investi-
gation only in patients for whom there is persistent 
concern about symptoms, or to refer for CTC, which 
allows imaging of both colonic and extracolonic regions 
of the abdomen and pelvis in one examination, but does 
not detect all extracolonic cancers and might oﬀ er false 
reassurance that an extracolonic cause of symptoms has 
been ruled out. It is not clear which is the best strategy, 
and both could result in patients undergoing additional 
investigation without clinical beneﬁ t.
Previous studies suggest that adverse events are more 
frequent after colonoscopy than after CTC;3–5 we were 
unable to corroborate this ﬁ nding because serious 
adverse events were rare in both groups. However, in a 
report published elsewhere,17 we have conﬁ rmed results 
from previous studies6–8 showing that patients ﬁ nd CTC 
more accept able than colonoscopy. Patients allocated 
colonoscopy in our trial were more satisﬁ ed with the way 
results were delivered (since this was more likely to 
happen immediately and via a face-to-face conversation), 
but reported more physical discomfort and worry, and 
were signiﬁ cantly less satisﬁ ed with the test than were 
patients in the CTC group.17
The health economic analysis of the trial is reported 
elsewhere.18 The higher unit cost of colonoscopy was 
largely oﬀ set by the greater number of additional 
procedures needed to investigate suspected colonic 
lesions in the CTC group. The mean diﬀ erence in net 
costs at 2010–11 prices was a statistically insigniﬁ cant 
£65 per patient in favour of CTC. The detection rate of 
colonic lesions by colonoscopy was only slightly higher 
than the detection rate for CTC, with an incremental cost 
of £9270 per case detected. As a result, neither method 
shows clear superiority in terms of cost-eﬀ ectiveness for 
detecting colonic lesions.
In conclusion, in our pragmatic trial of symptomatic 
patients, CTC was associated with a high referral rate 
for additional tests. These referrals have the potential to 
increase anxiety and overall cost, and—in patients 
referred for colonoscopy—mitigate the advantage of 
avoiding an endoscopic examination. For most patients, 
however, CTC oﬀ ers a similarly sensitive, less invasive 
alternative to colonoscopy. With wider implementation, 
Panel: Research in context
Systematic review
We searched the Medline database for reports on CT colonography (CTC), published 
between 1994 and 2003, using the terms “colonography”, “colography”, “CT colonoscopy”, 
“CT pneumocolon”, “virtual colonoscopy”, and “virtual endoscopy”. We did not apply any 
language restrictions. Additional searches using the Cochrane controlled trials register, 
Embase, Science Citation Index, and manual searches of key journals did not reveal any 
additional studies. 24 studies that met selection criteria were included in a meta-analysis, 
which showed that CTC has comparable sensitivity to colonoscopy for detection of colorectal 
cancer. However, we found no randomised trials comparing CTC with colonoscopy.
Interpretation
Our study is the ﬁ rst randomised trial to compare CTC and colonoscopy for investigation 
of patients with symptoms suggestive of colorectal cancer. We report that CTC generated 
substantially more follow-up tests than colonoscopy. Almost half the referrals after CTC 
were for smaller polyps or clinical uncertainty, with a low probability of ﬁ nding cancer or 
a large polyp. Many of these follow-up investigations might be avoided by the 
development of guidelines for patient referral and the use of techniques such as faecal 
tagging to increase speciﬁ city. Previous evidence suggests that CTC is a similarly 
sensitive, less invasive alternative to colonoscopy, and we found that it was preferred by 
patients. CTC might be a particularly suitable test in patients with low-risk symptoms, or 
in those who are older or have comorbidities. Women might also beneﬁ t from having 
CTC, as they have a higher rate of incomplete colonoscopy and generally have fewer 
polyps than men do. Our results suggest that more widespread use of CTC as an 
alternative to colonoscopy is justiﬁ ed, provided that guidelines on best practice and a 
system of training and audit are put in place.
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there will be a need for protocols to improve speciﬁ city, 
along with attention to referral criteria and an emphasis 
on radiologist training and assessment. With these in 
place, our results suggest that CTC should be considered 
as an alternative ﬁ rst-line investigation for patients with 
symptoms suggestive of colorectal cancer.
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